Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Ann R Coll Surg Engl ; 99(5): 358-362, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28462656

RESUMEN

BACKGROUND Intravenous calcium supplements are often required following parathyroidectomy to avoid postoperative hypocalcaemia. The aim of this study was to compare application effect of a femoral central venous catheter (CVC) and peripherally inserted central catheter (PICC) on intravenous calcium supplements after parathyroidectomy. METHODS We retrospectively reviewed the hospital records of 73 patients with secondary hyperparathyroidism who underwent a successful parathyroidectomy at the Huashan Hospital attached to Fudan University between 1 April 2011 and 1 February 2016. RESULTS Of the 73 study participants, 39 (53.4%) had a PICC and 34 (46.6%) had a CVC, respectively. Patients in the CVC group needed 6-7 days of intravenous calcium supplements, while patients in PICC group needed only 2-3 days to achieve normal serum calcium concentration (2.2-2.6 mmol/L). Furthermore, the duration of calcium supplementation was 71.62 ± 4.48 hours in PICC group and 100.4 ± 5.43 hours in CVC group (P < 0.05). Of the patients in PICC group, the incidence of catheter occlusion, operation failure and hypocalcaemia was 0%, which was significantly lower than those in CVC group (2.56%, 7.69% and 7.69%, respectively). CONCLUSIONS PICC is a safe and efficient alternative in contrast to CVC for providing venous access for calcium supplementation in surgical patients after parathyroidectomy.


Asunto(s)
Calcio , Cateterismo Venoso Central/estadística & datos numéricos , Cateterismo Periférico/estadística & datos numéricos , Paratiroidectomía , Administración Intravenosa , Calcio/administración & dosificación , Calcio/sangre , Calcio/uso terapéutico , Femenino , Humanos , Hiperparatiroidismo Secundario/cirugía , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
2.
Zhonghua Yi Shi Za Zhi ; 47(5): 262-272, 2017 Sep 28.
Artículo en Chino | MEDLINE | ID: mdl-29874717

RESUMEN

In the Huang di nei jing(Huangdi's Internal Classic), jin ye (fluid and humor) is described in two senses, broad and narrow, though not so strictly.Sometimes, jin ye is explained ambiguously as "sweat" and "urine" , as in the phrase "the bladder, being a house of jin ye" , here "jin ye" refers to the urine. In the Qi jue lun pian of Su wen (Chapter on Qi-Syncope of Plain Questions) , the "bao" in the sentence "heat of bao moved to bladder" refersto the uterus. In the Shi cong rong lun pian (Chapter of Readily Inspecting) of Plain Questions, the "bladder" in the phrase "gallbladder, stomach, large intestine, small intestine, spleen, bao and bladder" , which, being an annotation of "bao" originally, is mistakenly incorporated into the text of the Classic. In the Wu wei lun of Ling shu (On Five Tastes in Miraculous Pivot) , the "bao" in "bao of bladder" refers to the external hou (external manifestation) of the bladder, that is the scrotum. In the Bei ji qian jin yao fang (Essential Prescriptions Worth a Thousand Gold for Emergencies) , the short sentence "pang guang zou bao" is an error in itself. In the sentence of "settled in the bao and zhi causing to dream of defecation and urination" in the Yin xie fa meng (Dreams due to Evils) of Miraculous Pivot, "bao" refers to uterus, and "zhi" to anus. In Bi lun pian(Chapter on Impediment) of Plain Questions, "the man suffered bao bimight feel internal pain when the lesser abdomen and bladder are pressed" , here, "bao" refers to the bladder. In the Wu yin wu wei(Chapter on Five Sound and Five Tastes) of Miraculous Pivot, the "bao" in the sentence "thoroughfare vessel and conception vessel all starts from bao" , again, "bao" here refers to the bladder, rather than to the uterus. From the above descriptions of "bladder" and "bao" in the Huangdi's Internal Classic, the "bladder" in ancient medical books refers to the substantial bladder, an anatomical organ, and "bao" refers to cystiform organs, including the bladder, uterus, scrotum etc.


Asunto(s)
Medicina Tradicional China , Vejiga Urinaria/fisiología , Libros , Humanos , Orina
3.
Biofactors ; 15(1): 27-38, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11673642

RESUMEN

A novel selenium form, nano red elemental selenium (Nano-Se) was prepared by adding bovine serum albumin to the redox system of selenite and glutathione. Nano-Se has a 7-fold lower acute toxicity than sodium selenite in mice (LD(50) 113 and 15 mg Se/kg body weight respectively). In Se-deficient rat, both Nano-Se and selenite can increase tissue selenium and GPx activity. The biological activities of Nano-Se and selenite were compared in terms of cell proliferation, enzyme induction and protection against free racial-mediated damage in human hepatoma HepG2 cells. Nano-Se and selenite are similarly cell growth inhibited and stimulated synthesis of glutathione peroxidase (GPx), phospholipid hydroperoxide glutathione peroxidase (PHGPx) and thioredoxin reductase (TR). When HepG2 cells were co-treated with selenium and glutathione, Nano-Se showed less pro-oxidative effects than selenite, as measured by cell growth. These results demonstrate that Nano-Se has a similar bioavailability in the rat and antioxidant effects on cells.


Asunto(s)
Selenio/farmacología , Disponibilidad Biológica , Carcinoma Hepatocelular , Muerte Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Radicales Libres , Glutatión/farmacología , Glutatión Peroxidasa/biosíntesis , Glutatión Peroxidasa/metabolismo , Inhibidores de Crecimiento/farmacología , Humanos , Cinética , Neoplasias Hepáticas , Paraquat/farmacología , Selenio/deficiencia , Selenio/farmacocinética , Selenio/toxicidad , Selenito de Sodio/toxicidad , Reductasa de Tiorredoxina-Disulfuro/biosíntesis , Células Tumorales Cultivadas
5.
Am J Chin Med ; 22(3-4): 321-7, 1994.
Artículo en Inglés | MEDLINE | ID: mdl-7872244

RESUMEN

According to the theory of Traditional Chinese Medicine (TCM), 50 patients with affective disorders were typed into the categories of depressed liver resulting in fire, mild Yang deficiency and mild Yin deficiency and were treated with Xiao Yao San Jia Wei. The results are 26 patients with marked improvement, 17 patients with improvement and 7 patients with no improvement.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Trastornos del Humor/diagnóstico , Trastornos del Humor/tratamiento farmacológico , Trastorno Bipolar/diagnóstico , Trastorno Bipolar/tratamiento farmacológico , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/tratamiento farmacológico , Humanos , Medicina Tradicional China , Resultado del Tratamiento , Deficiencia Yang/diagnóstico , Deficiencia Yang/tratamiento farmacológico , Deficiencia Yin/diagnóstico , Deficiencia Yin/tratamiento farmacológico
6.
Contraception ; 38(6): 641-57, 1988 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-3146463

RESUMEN

A large scale, phased investigation of NORPLANT contraceptive systems was conducted in the People's Republic of China. The first phase comprehended 1,200 women in four cities. Expanded trials included 11,918 women at 12 major centers and at sub-centers by 31 May 1987. At that date 4,676 NORPLANT capsule subjects and 1,089 rod subjects had completed one year of use, 1,381 capsule acceptors had completed two years as had 197 rod users. Gross pregnancy rates were less than 0.1 per 100 for each implant type both at one and at two years. Continuation rates were 94 per 100 for each implant type at one year, and were 82.0 and 83.6 per 100 among users of NORPLANT capsule and rod implants, respectively, at two years. Disruption of menstrual function was the dominant reason for termination, but mean hemoglobin levels increased in each of the nine centers reporting values at admission and at one year. First year gross cumulative termination rates for medical reasons were 1.2 to 1.3 per 100, reaching 3.8 and 5.6 per 100 for capsule and rod implants, respectively, at two years. Microdose contraception with these levonorgestrel-releasing implants appears to be a highly acceptable and effective modality suitable for Chinese women. NORPLANT implants are now approved by the national drug regulatory agency for general use in China.


Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Norgestrel/normas , Adolescente , Adulto , Sistema Cardiovascular/fisiopatología , China , Anticonceptivos Femeninos/efectos adversos , Anticonceptivos Femeninos/normas , Implantes de Medicamentos , Femenino , Humanos , Levonorgestrel , Trastornos de la Menstruación , Norgestrel/efectos adversos , Recuento de Plaquetas , Embarazo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA